Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase NA 4Phase 4 3Phase 3 2Phase 1/2 2Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Neurofibromatosis 2 1Melanoma 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Doxycycline × Clear all
NCT05521048 2025-12-08

Doxycycline in Cutaneous Schwannoma (NF2)

Massachusetts Eye and Ear Infirmary

Phase 1/2 Active not recruiting
19 enrolled
CNS

Neurofibromatosis 2

NCT01590082 2020-09-02

Doxycycline, Temozolomide and Ipilimumab in Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
12 enrolled 6 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡